

Managing nmCRPC in the era of second-generation ARIs

Thursday 22 September 2022

17:00–18:00 (SGT)

台灣時間：9月22日（四） 17:00-18:00

Prostate Cancer International Medical Exchange (PRIME) is a forum facilitating international, expert-led interactions between medical professionals working in prostate cancer.

Join us in September for the second PRIME meeting of 2022, which will focus on managing high-risk nmCRPC with second-generation ARIs.

Register to attend online



Meeting attendees will have the opportunity to engage with the expert panel and exchange ideas with international colleagues via the meeting platform.

THE PANEL AND AGENDA



Professor Howard Gurney,
Oncologist
Macquarie University,
Australia



Professor Bertrand Tombal,
Urologist
Université catholique de
Louvain, Belgium



Professor Heather Payne,
Oncologist
University College London Hospitals
NHS Foundation Trust, UK



Associate Professor
John Shyi Peng Yuen, Urologist
Singapore General Hospital,
Singapore

Time	Topic	Speaker/Moderator
17:00-17:05 (5 min)	Welcome and introduction	Prof. Howard Gurney
17:05-17:25 (20 min)	Management of nmCRPC	Prof. Bertrand Tombal
17:25-17:55 (30 min)	Panel discussion and audience Q&A	Prof. Howard Gurney, Prof. Bertrand Tombal, Prof. Heather Payne, Assoc. Prof. John Shyi Peng Yuen
17:55-18:00 (5 min)	Concluding remarks	Prof. Howard Gurney

The PRIME meeting series is organised and funded by Bayer.

Abbreviations: ARI, androgen receptor inhibitor; nmCRPC, non-metastatic castration-resistant prostate cancer.



© 2022 Bayer. All rights reserved.

*您之前同意本公司使用您的個資

聯絡我們 | 隱私權保護聲明 | 取消訂閱 | 同意聲明